CSBabyBiome: Timing of Maternal Antibiotic Prophylaxis During a Cesarean Section and the Early Infant Gut Microbiome

Sponsor
University Medical Center Groningen (Other)
Overall Status
Completed
CT.gov ID
NCT06030713
Collaborator
(none)
33
1
2
48
0.7

Study Details

Study Description

Brief Summary

In this study, investigators seek to determine whether the timing of antibiotics given to mothers during an elective C-section affects the composition of their infant's gut microbiome. To do this, a randomized controlled trial (RCT) was carried out with women undergoing elective C-sections. These women were either given antibiotics before the skin incision (AB+) or after the umbilical cord was clamped (AB-).

Detailed Description

Rationale: During a caesarean delivery, umbilical cord clamping can occur before or after administering a perioperative prophylactic antibiotic to the mother. If the cord is clamped before the antibiotic administration, this antibiotic cannot reach the infant. Conversely, if the cord is clamped after the antibiotic administration, these maternal antibiotics cross the placenta and enter the infant's circulation. In this study, investigators hypothesize that such antibiotics modify the composition and functionality of the neonatal gut microbiome. A changed neonatal microbiome associates with the onset of asthma, allergies, type 1 diabetes, and obesity later in life. Such a small intervention could influence the future health of the infant significantly.

Objective: The primary aim of this study is to contrast the composition and functionality of the neonatal gut microbiome from mothers given antibiotic prophylaxis before skin incision with the microbiome of neonates from mothers given the antibiotic after umbilical cord clamping during an elective caesarean delivery.

Study design: Randomized controlled trial

Study population: Pregnant women at >38 weeks of gestation undergoing elective caesarean section at the UMCG will be randomized into two groups. The gut microbiome of the neonates from both groups will be analyzed.

Intervention: The timing of umbilical cord clamping differs between the two groups. One gram of Cefazolin (once, intravenous) will be administered to one group before skin incision, while 1g cefazolin will be given to another group after umbilical cord clamping during an elective caesarean section.

Main study parameters/endpoints: The primary endpoint of this study is the variance in the composition and functionality of the neonatal gut microbiome over a year, contrasting neonates from mothers given antibiotic prophylaxis before skin incision with neonates from mothers given the antibiotic after umbilical cord clamping.

Study Design

Study Type:
Interventional
Actual Enrollment :
33 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Timing of umbilical cord clamping is different in the two arms. One gram of Cefazolin (once, intravenous) will be given to one group of women before skin incision compared to 1g cefazolin given to another group of women after umbilical cord clamping during an elective caesarean section.Timing of umbilical cord clamping is different in the two arms. One gram of Cefazolin (once, intravenous) will be given to one group of women before skin incision compared to 1g cefazolin given to another group of women after umbilical cord clamping during an elective caesarean section.
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Timing of Umbilical Cord Clamping During an Elective Caesarean Delivery and Its Association With Neonatal Gut Microbiome.
Actual Study Start Date :
Mar 1, 2019
Actual Primary Completion Date :
Oct 1, 2022
Actual Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Cord clamped after antibiotic prophylaxis

Umbilical cord clamped after 1g of cephazolin

Drug: Cefazolin
Cord clamping before or after antibiotic (cefazolin) prophylaxis
Other Names:
  • DB01327
  • J01DB04
  • Experimental: Cord clamped before antibiotic prophylaxis

    Umbilical cord clamped before 1g of cephazolin

    Drug: Cefazolin
    Cord clamping before or after antibiotic (cefazolin) prophylaxis
    Other Names:
  • DB01327
  • J01DB04
  • Outcome Measures

    Primary Outcome Measures

    1. Infant microbial species level differences between two groups [First 6 weeks of life]

      Centered log ratio transformed relative abundance differences of bacterial species (relative abundance of > 0.05% and present in at least 2 infants) between two interventional groups

    2. Infant Alpha Diversity differences between two groups [First 6 weeks of life]

      Alpha Diversity difference measured by the Shannon Diversity Index of infant microbiome at species level between two interventional groups

    3. Infant Beta Diversity differences between two groups [First 6 weeks of life]

      Beta Diversity difference in Aitchison distances between the two intervention groups

    4. Infant Antibiotic Resistance total gene load differences between two groups [First 6 weeks of life]

      Infant Antibiotic Resistance total gene load differenced measured in RPKM between the two interventional groups

    Secondary Outcome Measures

    1. Number of participants with post c-section maternal wound infection [First 6 weeks of life]

      Number of participants with early and late post C-section wound infection in mothers

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 1 Year
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Females undergoing elective CS at the UMCG

    • Gestational age in weeks equal to or above 38 weeks

    Exclusion Criteria:
    • Cephalosporin allergy

    • Exposure to antibiotic agent 2 weeks before CS

    • Temperature >37.5 C before CS

    • Pre-labour rupture of membranes

    • Emergency CS

    • No -20 freezer at home

    • No command of the Dutch language

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Medical Center Groningen Groningen Netherlands 9713 GZ

    Sponsors and Collaborators

    • University Medical Center Groningen

    Investigators

    • Principal Investigator: Trishla Sinha, MD, University Medical Center Groningen
    • Principal Investigator: Alexandra Zhernakova, MD/PhD, University Medical Center Groningen

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Medical Center Groningen
    ClinicalTrials.gov Identifier:
    NCT06030713
    Other Study ID Numbers:
    • CS_Baby_Biome_2017/240
    • NL61493.042.17
    • METc 2017.240
    First Posted:
    Sep 11, 2023
    Last Update Posted:
    Sep 13, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 13, 2023